Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis

Oncotarget. 2017 May 30;8(22):36857-36868. doi: 10.18632/oncotarget.16143.

Abstract

Background: Inflammation was considered to perform crucial roles in the development and metastasis of malignancies. A heightened neutrophil-lymphocyte ratio has been described to be associated with detrimental survivals in different malignancies. Debate remains over the impact of heightened neutrophil-lymphocyte ratio on survivals in biliary tract cancer. The review evaluated the prognostic value of neutrophil-lymphocyte ratio in biliary tract cancer.

Methods: MEDLINE, the Cochrane Library, EMBASE, and the Chinese SinoMed were systematically searched for relevant articles. Associations between neutrophil-lymphocyte ratio and long-term outcomes were expressed as the hazard ratios and 95% confidence intervals. The odds ratio was utilized to assess the association between neutrophil-lymphocyte ratio and clinicopathological parameters.

Results: Fourteen studies consisting of 3217 patients were analyzed: 1278 (39.73%) in the high pretreatment neutrophil-lymphocyte ratio group and 1939 (60.27%) in the low pretreatment neutrophil-lymphocyte ratio one. The results proved that heightened pretreatment neutrophil-lymphocyte ratio was significantly associated with detrimental overall survival and relapse free survival for biliary tract cancer patients. In addition, elevated neutrophil-lymphocyte ratio was positively correlated with higher carbohydrate antigen 19-9 levels, advanced TNM staging and greater lymph node involvement.

Conclusion: This meta-analysis marked that an increased pretreatment neutrophil-lymphocyte ratio was significantly linked with detrimental long-term outcomes and clinicopathological parameters for patients with biliary tract cancer.

Keywords: biliary tract cancer; neutrophil-lymphocyte ratio; overall survival; prognosis; relapse free survival.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Biliary Tract Neoplasms / blood*
  • Biliary Tract Neoplasms / mortality*
  • Biliary Tract Neoplasms / pathology
  • Biliary Tract Neoplasms / therapy
  • Biomarkers
  • Humans
  • Leukocyte Count*
  • Lymphocyte Count*
  • Lymphocytes*
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neutrophils*
  • Prognosis
  • Publication Bias

Substances

  • Biomarkers